半亩花田赴港上市 毛利超60%净利率不足8% 营销又砸钱
Nan Fang Du Shi Bao·2026-01-19 13:49

Core Viewpoint - The company, Shandong Huawutang Cosmetics Co., Ltd. (parent company of Banmu Huatian), is set to become the first domestic beauty brand listed on the Hong Kong Stock Exchange in 2026, showcasing significant growth in revenue but facing challenges with profitability due to high marketing expenditures [1][2]. Financial Performance - The company reported revenues of CNY 1.199 billion and CNY 1.499 billion for 2023 and 2024, respectively, representing a year-on-year growth of 25% [2]. - Adjusted net profit for 2023 was CNY 23.7 million, expected to rise to CNY 82.8 million in 2024, marking a staggering increase of 249.4% [2]. - For the first nine months of 2025, the adjusted net profit is projected to reach CNY 148 million, a year-on-year growth of 197.2% [2]. - The adjusted net profit margins are low, at 2% for 2023 and 5.5% for 2024, with gross margins of 65.8% and 62.3% respectively [3][4]. Marketing and Sales Expenditure - Sales and marketing expenses accounted for 53.2% and 45.2% of total revenue in 2023 and 2024, respectively, indicating a significant portion of revenue is consumed by these costs [4]. - The company anticipates that sales and distribution expenses will continue to rise alongside business growth, highlighting a reliance on marketing for future revenue increases [4]. Revenue Channels and Product Lines - The company heavily relies on online channels, with online revenue constituting 85.7% and 75.9% of total revenue in 2023 and 2024, respectively [5]. - The product portfolio includes body care, hair care, and facial care, with body care maintaining a stable revenue contribution around 45% [5][6]. - Hair care products have seen a significant increase in revenue contribution, rising from 3.6% in 2023 to 25.4% in the first nine months of 2025, indicating a new growth avenue [6]. Financial Structure and Future Outlook - The company operates primarily on an OEM model, which may limit its control over core technologies, and its R&D expenditure is relatively low at 2.4% and 2.1% of total revenue for 2023 and 2024, respectively [7]. - Cash flow from operating activities was approximately CNY 137 million for the first nine months of 2025, but financing cash flow turned negative starting in 2024, indicating potential liquidity issues [8]. - The company may seek to go public to optimize its debt structure and replenish its capital pool for further expansion [8].